Author

C. Hemez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:clinical cohort / trial· 1 Organism:human· 1

Frequent Co-Authors

P. Abel zur Wiesch· 2 shared A. C. Palmer· 1 shared A. H. Diacon· 1 shared A. Martinecz· 1 shared F. Clarelli· 1 shared L. Chindelevitch· 1 shared M. J. Boeree· 1 shared R. Dawson· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

P. Abel zur Wiesch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: evidence for heteroresistance

A. Martinecz, M. J. Boeree, A. H. Diacon, R. Dawson, C. Hemez, R. E. Aarnoutse, P. Abel zur Wiesch

This study shows that higher rifampicin peak concentrations accelerate the slow phase of bacterial decline in tuberculosis, supporting heteroresistance as the mechanism.

bioRxiv · Jun 6, 2022Microbiology

Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations

C. Hemez, F. Clarelli, A. C. Palmer, L. Chindelevitch, T. Cohen, P. Abel zur Wiesch

This study models how antibiotic mechanisms affect resistance mutation fitness, finding that drug type has little impact on resistance selection but that heterogeneous binding enables secondary mutations under certain conditions.

bioRxiv · Jun 1, 2020Pharmacology & Toxicology